NCT00372853

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

A Phase 1 Dose Escalation Trial To Evaluate The Safety And Tolerability Of CP-675,206 Administered In Combination With SU011248 To Patients With Metastatic Renal Cell Carcinoma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.

Conditions

• Carcinoma, Renal Cell

Interventions

Type	Name	Description
DRUG	CP-675,206	CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
DRUG	SU011248	SU011248 administered at a dose of 37.5mg/day every day.
DRUG	CP-675,206	CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
DRUG	SU011248	SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.

Timeline

• Start date: 2006-11-01
• Primary completion: 2010-05-01
• Completion: 2010-05-01
• First posted: 2006-09-07
• Last updated: 2012-06-06

Locations

5 sites across 1 country: United States